Company Description

In2Cell Biosciences is an early-stage company building POLEX, a platform that reads a drug's impact directly on the tumour genome. Instead of dosing by protocol and hope, POLEX shows whether a treatment is actually reaching the tumour, so patients aren't blindsided by a drug that was never going to work.